» Articles » PMID: 34945148

Enhancing Endocannabinoid Control of Stress with Cannabidiol

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Dec 24
PMID 34945148
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The stress response is a well-defined physiological function activated frequently by life events. However, sometimes the stress response can be inappropriate, excessive, or prolonged; in which case, it can hinder rather than help in coping with the stressor, impair normal functioning, and increase the risk of somatic and mental health disorders. There is a need for a more effective and safe pharmacological treatment that can dampen maladaptive stress responses. The endocannabinoid system is one of the main regulators of the stress response. A basal endocannabinoid tone inhibits the stress response, modulation of this tone permits/curtails an active stress response, and chronic deficiency in the endocannabinoid tone is associated with the pathological complications of chronic stress. Cannabidiol is a safe exogenous cannabinoid enhancer of the endocannabinoid system that could be a useful treatment for stress. There have been seven double-blind placebo controlled clinical trials of CBD for stress on a combined total of 232 participants and one partially controlled study on 120 participants. All showed that CBD was effective in significantly reducing the stress response and was non-inferior to pharmaceutical comparators, when included. The clinical trial results are supported by the established mechanisms of action of CBD (including increased N-arachidonylethanolamine levels) and extensive real-world and preclinical evidence of the effectiveness of CBD for treating stress.

Citing Articles

Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims.

Engeli B, Lachenmeier D, Diel P, Guth S, Villar Fernandez M, Roth A Nutrients. 2025; 17(3).

PMID: 39940347 PMC: 11820564. DOI: 10.3390/nu17030489.


New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population.

Danilowska K, Picheta N, Zyla D, Piekarz J, Zych K, Gil-Kulik P J Clin Med. 2024; 13(12).

PMID: 38930098 PMC: 11204858. DOI: 10.3390/jcm13123567.


Behavioral observations, heart rate and cortisol monitoring in horses following multiple oral administrations of a cannabidiol containing paste (part 2/2).

Eichler F, Ehrle A, Machnik M, Jensen K, Wagner S, Baudisch N Front Vet Sci. 2024; 10:1305873.

PMID: 38234983 PMC: 10791836. DOI: 10.3389/fvets.2023.1305873.


Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review.

Singh K, Bhushan B, Chanchal D, Sharma S, Rani K, Yadav M Behav Neurol. 2023; 2023:8825358.

PMID: 37868743 PMC: 10586905. DOI: 10.1155/2023/8825358.


Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial.

Suzuki J, Prostko S, Szpak V, Chai P, Spagnolo P, Tenenbaum R Front Psychiatry. 2023; 14:1155984.

PMID: 37065899 PMC: 10098189. DOI: 10.3389/fpsyt.2023.1155984.


References
1.
Padgett D, Glaser R . How stress influences the immune response. Trends Immunol. 2003; 24(8):444-8. DOI: 10.1016/s1471-4906(03)00173-x. View

2.
Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M . Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial. Dig Dis Sci. 2017; 62(6):1615-1620. DOI: 10.1007/s10620-017-4540-z. View

3.
Micale V, Di Marzo V, Sulcova A, Wotjak C, Drago F . Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther. 2012; 138(1):18-37. DOI: 10.1016/j.pharmthera.2012.12.002. View

4.
Lee J, Bertoglio L, Guimaraes F, Stevenson C . Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol. 2017; 174(19):3242-3256. PMC: 5595771. DOI: 10.1111/bph.13724. View

5.
Chatterton Jr R, Vogelsong K, Lu Y, Ellman A, HUDGENS G . Salivary alpha-amylase as a measure of endogenous adrenergic activity. Clin Physiol. 1996; 16(4):433-48. DOI: 10.1111/j.1475-097x.1996.tb00731.x. View